Trophos Posts Results of Phase III Study of Olesoxime

Olesoxime did not demonstrate significant benefit on the primary endpoint of survival after 18 months of treatment over that of riluzole.

Trophos SA announced the results from the phase III study of olesoxime in patients with ALS.

The study was an 18-month randomized, parallel group, double-blind, placebo-controlled trial evaluating the efficacy and safety of olesoxime against placebo in patients treated with riluzole.

The study was conducted in 512 patients diagnosed with ALS between six and thirty six months before enrolment and receiving standard care. Olesoxime was dosed orally at 330 mg once-a-day.

Olesoxime did not demonstrate significant benefit on the primary endpoint of survival after 18 months of treatment over that of riluzole. A trend was seen on the seco